



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

BEST AVAILABLE COPY

Signed

Stephen Hordley

Dated 9 December 2004

**CERTIFIED COPY OF
PRIORITY DOCUMENT**

Patents Form 1/77


Patents Act 1977
(Rule 16)

The
Patent
Office

26MAR98 E348690-1-002866
P01/7700 25.00 9306442.1

Request for grant of a patent

(See the notes on the back of this form. You can also get
an explanatory leaflet from the Patent Office to help
you fill in this form)



The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

DUNW/P18811GB

2. Patent application number

(The Patent Office will fill in this part)

26 MAR 1998

9806442.1

3. Full name, address and postcode of the or of
each applicant (underline all surnames)

University of Dundee

Dundee DD1 4HN
United Kingdom

Patents ADP number (if you know it)

If the applicant is a corporate body, give the
country/state of its incorporation

United Kingdom

798 207601

4. Title of the invention

ENZYME INHIBITION

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom
to which all correspondence should be sent
(including the postcode)

ERIC POTTER CLARKSON
PARK VIEW HOUSE
58 THE ROPEWALK
NOTTINGHAM
NG1 5DD

Patents ADP number (if you know it)

1305010

6. If you are declaring priority from one or more
earlier patent applications, give the country
and the date of filing of the or of each of these
earlier applications and (if you know it) the or
each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise
derived from an earlier UK application,
give the number and the filing date of
the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right
to grant of a patent required in support of
this request? (Answer yes if:

YES

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an
applicant, or
- c) any named applicant is a corporate body
See note (d))

ENZYME INHIBITION

The present invention relates to enzyme inhibition, and in particular to the inhibition of an enzyme that we call asparaginyl endopeptidase which we
5 have found is involved in processing antigens, particularly microbial antigens, by the immune system.

The immune response to protein antigens involves a large number of individual gene products, and new ones are still being discovered. In
10 some cases the gene products were known *per se*, but not known to be involved in the immune response.

An immune response may be raised towards foreign antigens, for example, antigens associated with microorganisms, or the immune
15 response may be caused by a response to a self antigen (autoimmunity). In either case, there exists the need for methods and means for modulating the immune system and how it responds to these foreign and self antigens.

Because proteins must be proteolytically processed (ie partially degraded)
20 before the T cells of the immune system can respond, one set of proteins of importance in an immune response are proteolytic enzymes (proteases). It is typically proteolysed proteins (ie protein fragments) which are presented by antigen presenting cells on MHC Class I or Class II molecules.

25

Several different aspartic and cysteine proteases are thought to be involved in invariant chain and antigen processing (see, for example, Fineschi & Miller (1997) *Trends Biochem. Sci.* 22, 377-382; and Chapman (1998)

presentation of peptides on Class II MHC molecule-containing cells (and to substantially inhibit T cell activation).

An enzyme with AEP activity is readily able to cleave the substrate Z-Ala-Ala-Asn-7-(4-methyl)coumarylamide to release a fluorescent product, where Z is benzyloxy carbonyl.

By an "inhibitor of asparaginyl endopeptidase" we include any suitable inhibitor. The inhibitor may be a competitive inhibitor or it may be a non-competitive inhibitor. AEP is a cysteine protease and so inhibitors which chemically react with the active cysteine residue are suitable and are, typically, irreversible inhibitors. Other amino acid residues, such as histidine, may be present at the active site and inhibitors which react with any active site residue are suitable.

15

In one embodiment of the invention the AEP inhibitor is a competitive inhibitor. Typically, the competitive inhibitor is a peptide comprising an asparagine-containing peptide. Suitably, the peptide is a peptide comprising a known AEP cleavage site but which, because of its affinity for AEP can compete for another AEP cleavage site and substantially prevent cleavage at the said other cleavage site if present in sufficient concentration. Known cleavage sites for AEP in tetanus toxin are described in Chen *et al* (1997) *J. Biol. Chem.* 272, 8090-8098.

25 In a preferred embodiment of the invention the competitive inhibitor has the general structure $(X_1)_p N(X_2)_q$ wherein X_1 and X_2 are amino acid residues, N is an asparagine residue, p is 3 to 6 and q is 1 to 3.

ninhydrin, trinitrobenzene sulphonic acid or isotin test procedures. Upon completion of synthesis, peptides are cleaved from the resin support with concomitant removal of side-chain protecting groups by treatment with 95% trifluoroacetic acid containing a 50% scavenger mix. Scavengers commonly used are ethanedithiol, phenol, anisole and water, the exact choice depending on the constituent amino acids of the peptide being synthesised. Trifluoroacetic acid is removed by evaporation *in vacuo*, with subsequent trituration with diethyl ether affording the crude peptide. Any scavengers present are removed by a simple extraction procedure which on lyophilisation of the aqueous phase affords the crude peptide free of scavengers. Reagents for peptide synthesis are generally available from Calbiochem-Novabiochem (UK) Ltd, Nottingham NG7 2QJ, UK. Purification may be effected by any one, or a combination of, techniques such as size exclusion chromatography, ion-exchange chromatography and (principally) reverse-phase high performance liquid chromatography. Analysis of peptides may be carried out using thin layer chromatography, reverse-phase high performance liquid chromatography, amino-acid analysis after acid hydrolysis and by fast atom bombardment (FAB) mass spectrometric analysis.

20

In a further embodiment, the inhibitor may be a non-competitive or irreversible inhibitor. AEP activity can be blocked by high concentrations of inhibitors which block all cysteine proteases and some serine proteases. However, it is particularly preferred that the inhibitors are selective for AEP.

25

Generally, irreversible AEP inhibitors may be any of peptide aldehydes, peptide chloromethyl ketones, peptide fluoromethyl ketones, peptide

Typically, peptide aldehyde inhibitors have the structure:

Acetyl (or other blocking group)-X_n-Asparaginal

5

where X is an amino acid residue and n is between 1 and 100, preferably between 1 and 50, more preferably between 1 and 10 and typically 2 to 6.

A suitable peptide aldehyde includes acetyl-alanyl-glutamyl-asparaginal.

10

Elastatinal blocks AEP activity; however a more specific variant, in which the C terminal amino residue is replaced by asparagine, may be useful.

Figure 4 shows the structures of some useful inhibitors.

15

Typically, peptide chloromethylketone inhibitors have the structure.

Acetyl (or other blocking group)-X_n-asparaginyl-chloromethyl ketone where X and n are as above.

20

A suitable peptide includes acetyl-alanyl-glutamyl-asparaginyl-chloromethylketone and acetyl-tyrosyl-valyl-alanyl-asparaginyl-chloromethylketone (analogous to ICE protease inhibitor YVAD-cmk); see Figure 4 for further details.

25

Typically, peptide fluoromethylketone inhibitors have analogous structures to peptide chloromethylketone inhibitors except for the replacement of a chloro group with a fluoro group.

It will be appreciated from the foregoing that AEP inhibitors may be designed based on other cysteine protease inhibitors such as E-64 (1-trans-epoxysuccinyl-leucylamide (4-guanido)-butane), Leupeptin (acetyl-leucyl-
5 leucyl-arginal), Antipain ([*(S)*-1-carboxy-2-phenyl]-carbamoyl-Arg-Val-arginal), Elastinal (N-[*(S)*-1-carboxy-isopentyl]-carbamoyl- α -(2-iminohexahydro-4(*S*)-pyrimidyl]-L-glycyl-L-glutaminyl-L-alaninal),
TLCK (tosyllysylchloromethylketone) and TPCK (tosylphenylalanylchloromethylketone), for example by introduction of an
10 asparaginyl residue at an appropriate place in place of an existing amino acid residue.

Vinyl sulphone inhibitors of cysteine proteases are described in Palmer *et al* (1995) *J. Med. Chem.* **38**, 3193-3196. Peptide aldehyde inhibitors of
15 cysteine proteases are described in Thomson *Methods Enzymol.* **46**, 220 - and Vinitsky *et al* (1994) *J. Biol. Chem.* **269**, 29860-29866 639-648. Peptide diazomethanes as inhibitors of cysteine proteases are described in Shaw (1994) *Methods Enzymol.* **244**, 649-656 and Shaw & green (1981) *Methods Enzymol.* **80**, 820-826. Peptide (aryloxy) methanes as inhibitors
20 of cysteine proteases are described in Krantz (1994) *Methods Enzymol.* **244**, 656-671. Peptide N,O-diarylhydroxamates as inhibitors of cysteine proteases are described in Brömme & Demuth (1994) *Methods Enzymol.* **244**, 671-685. Peptide chloromethyl ketones as inhibitors of cysteine proteases are described in Williams & Mann (1993) *Methods Enzymol.*
25 **222**, 503-513. Thus, methods for synthesising suitable inhibitors are well known to the person skilled in the art.

are not bound by any theory concerning the invention, we believe that AEP may play an important role in autoimmune disease because it may recognise and cleave at sites which are normally hidden by glycosylation at asparagine residues. Glycosylation at asparagine residues is common in mammalian proteins and glycosylated asparagine residues are not cleaved by AEP. An abnormal reduction in asparagine glycosylation of a self protein may lead to it being susceptible to AEP cleavage at these cryptic sites and, therefore, the peptide produced from the abnormally glycosylated protein may be susceptible to loading into and presentation to the immune system by Class II MHC molecules. Bacterial proteins, such as tetanus toxin, are typically not asparagine glycosylated and so, if they contain appropriate asparagine residues, are susceptible to degradation by AEP and presentation on Class II MHC molecules in any case.

Preferably, the diseases are autoimmune diseases and it is particularly preferred if the patient to be treated has or is at risk of an autoimmune disease such as rheumatoid arthritis, insulin-dependent diabetes mellitus, multiple sclerosis, Hashimoto's thyroiditis, coeliac disease, myasthenia gravis, pemphigus vulgaris, systemic lupus erythromatosus and Grave's disease.

The aforementioned inhibitors for use in the invention or a formulation thereof may be administered by any conventional method including oral, parenteral (eg subcutaneous or intramuscular) injection topical and the like. The treatment may consist of a single dose or a plurality of doses over a period of time.

comprising contacting the cell with an inhibitor of asparaginyl endopeptidase.

In one embodiment of the invention, a T cell causing a disease, such as one of the autoimmune diseases listed above, is transfected with a pool of cDNAs (or is contacted with proteins expressed from a pool of cDNAs) wherein the pool of cDNAs is believed to contain a cDNA encoding a protein which activated the T cell. The cDNA which encodes a protein which activates the T cell is selected and encodes a putative autoimmune protein. The assay may be carried out in the presence or absence of AEP inhibition in order to determine the involvement of AEP processing in the disease and also to determine any cryptic Asn glycosylation sites which may be important in the self-antigen immune response.

A further aspect of the invention provides a method of identifying a compound for modulating Class II MHC antigen processing the method comprising contacting a test compound with asparaginyl endopeptidase and selecting a compound which reduces its activity.

This method (or screening assay) of the invention is suitable carried out in a format which allows for many test compounds to be screened simultaneously such as in a 96-well plate format. The activity of AEP is conveniently measured using any suitable substrate but it is preferred if the substrate is one which, upon cleavage by AEP, gives rise to a readily-detectable product. For example, the product may be coloured or fluorescent or detectable in some other way. It is particularly preferred if the product is fluorescent; a preferred substrate is Z-Ala-Ala-Asn-7-(4-methyl)coumarylamide.

A further aspect of the invention comprises a non-human transgenic animal wherein a gene encoding asparaginyl endopeptidase has been modified and the animal expresses substantially no asparaginyl endopeptidase from said gene.

By "transgenic" animal we specifically include animals in which all or part of a gene have been "knocked out" or otherwise made substantially incapable of expressing an asparaginyl endopeptidase. Suitable mice can be made using standard methodology involving, for example, genetic manipulation of embryonic stem (ES) cells as is well known in the art. A cDNA encoding AEP is described in Chen *et al* (1997) *J. Biol. Chem.* 272, 8090-8096, and this information may be used in designing and making the transgenic animals of the invention.

It is particularly preferred if the non-human animal is a mouse, but it may be any suitable non-human animal including rat, rabbit and the like.

In a preferred embodiment of the invention, the non-human transgenic animal which expresses substantially no AEP from an AEP gene comprises a genetic background which predisposes the animal to an autoimmune disease either spontaneously or upon administration of protein antigen. Animals, especially mice, with a suitable genetic background are well known, for example NOD mice, which are a model for diabetes, EAE mice which are a model for allergic encephalomyelitis and CIA mice which are a model for collagen-induced arthritis. Such mice are described or referenced in Cantorna *et al* (1998) *J. Nutr.* 128, 68-72; Xiao & Link

and stained with Coomassie Blue. (b) Cleavage sites: TTCF digestion products were separated by SDS PAGE and electrophoretically transferred to nitrocellulose membrane. Individual fragments numbered 1-6 were subjected to 5 cycles of Edman degradation. N-terminal sequence obtained is shown in bold following upstream residues from TTCF (tetanus toxin numbering). The N-terminal sequence of His-tagged TTCF was obtained for fragments 1 and 3. (c) Residues Asn 1184 and Glu 1184 in TTCF were mutated to alanine (see Methods) and digestions performed as before. The mutation abolishes cleavage at the mutated site but not at the first site (doublet at 47 kD). In this experiment cleavage of the third site was minimal.

Figure 2: TTCF is processed by an asparaginyl endopeptidase. (a) Chromatography of the TTCF processing activity on Mono-S resin. Fractions eluted by NaCl gradient were incubated with the substrates Z-Ala-Ala-Asn-NHMec or Z-Phe-Arg-NHMec in the presence or absence of E64 (trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane). E64 had no inhibitory effect on the cleavage of Z-Ala-Ala-Asn-NHMec (not shown). (b) Fractions as above were incubated with 10 μ g TTCF in the presence or absence of E64 for 4 hours at 37°C prior to SDS-PAGE analysis. (c) Each fraction was analysed by SDS-PAGE and Western blotting. Electrophoretically transferred material was probed with an affinity purified antiserum raised against the peptide KGIGSGKVLKSGPQC from human legumain¹.

25

Figure 3: Peptide inhibitors of AEP block asparaginyl endopeptidase activity and TTCF processing *in vitro* and *in vivo*. (a) TTCF was digested with purified AEP in the presence or absence of 0.2 mg/ml of the peptides

Example 1: Asparaginyl endopeptidase is involved in processing and class II MHC presentation of a microbial antigen

Summary

5

Foreign antigens must be proteolytically processed to allow loading of peptides onto class II MHC molecules. To investigate which proteases might be involved we exposed a domain of the microbial antigen, tetanus toxin (TTCF) to disrupted lysosomes purified from a human B cell line.

10 Surprisingly, the dominant processing activity was not one of the known lysosomal cathepsins but rather an asparagine specific cysteine endopeptidase which we call AEP. This enzyme appears similar if not identical to a mammalian homologue of legumain¹, an asparaginyl endopeptidase found originally in plants and parasites^{2,3}. We designed
15 competitive peptide inhibitors of AEP which specifically block its asparaginyl endopeptidase activity and inhibit processing of TTCF *in vitro* and its presentation *in vivo* to T cells. Since N-glycosylation renders asparagine resistant to cleavage by AEP we suggest that this enzyme may represent a further example of the ability of the innate immune system to
20 focus its attention on microbial non-self.

To analyse processing of a foreign antigen without making prior assumptions about which enzymes are involved we exposed a 47 kD domain of the tetanus toxin antigen (TTCF) to disrupted lysosomes
25 isolated from the human B cell line EDR. As shown in Fig 1a, the antigen was fragmented to produce a discrete series of products at pH 4.5 but not at pH 7.0 and minimally at pH 6.0, confirming the lysosomal origin of the protease(s) involved (Fig 1a). Surprisingly, we could not

purified the TTCF processing activity from a crude B cell lysosome fraction to establish whether or not it was an asparaginyl endopeptidase. As shown in Figure 2b, a peak of TTCF processing activity eluted from a cation-exchange resin at 0.4M NaCl. This activity co-eluted precisely with an activity capable of cleaving the substrate Z-Ala-Ala-Asn-7-(4-methyl)coumarylamide substrate (Fig 2a). Another protease activity, presumably cathepsin L and/or B, capable of cleaving the substrate Z-Phe-Arg-NHMec, partially overlapped the asparaginyl endopeptidase activity (Fig 2a). However this activity was completely inhibited by E64 (Fig 2a) while both the TTCF and Z-Ala-Ala-Asn-NHMec processing activity were unaffected (Fig 2b) confirming that a novel cysteine endopeptidase was involved. To compare this activity to the recently described mammalian form of legumain we generated anti-peptide antisera to several regions of the mammalian preprolegumain sequence¹. Blotting of each fraction with an antisera to residues 125-140 (see methods) revealed the presence of a protein with the same mobility (35 kD) as purified pig kidney legumain which co-eluted with the TTCF and peptide substrate processing activity (Fig 2c). Finally, exactly the same processing sites were recognised by the crude lysosomal fraction, the partially purified TTCF processing activity and purified pig kidney legumain (Figs 1b & 2b, ref 1 and data not shown). Thus, mammalian legumain or a closely related enzyme, is present in human B lymphocytes and *in vitro*, is the major enzyme responsible for processing this antigen. We propose the name AEP (Asparaginyl endopeptidase) for this enzyme to distinguish it from the plant enzyme.

We decided to test the possibility that high concentrations of asparagine containing peptides might act as competitive inhibitors. As shown in Fig

simply due to non-specific toxicity. First, presentation to other clones recognising other regions of TTCF was not affected by the AENK competitor (eg AK 111, 71 and 33: Fig 3c). Secondly, there was a clear differential sensitivity to AENK versus AEQK (Fig 3c), strongly suggesting that specific inhibition of AEP was responsible for the slowed kinetics of presentation. Thirdly, the inhibitory effects of AENK could be overridden by using TTCF pre-digested *in vitro* by AEP. In other words, the requirement for AEP *in vivo*, and hence the inhibitory effect of AENK, was by-passed by AEP cleavage *in vitro* (data not shown). Taken together our results reveal AEP as a new and highly specific processing activity in the class II MHC pathway. Preliminary studies show that AEP is present in a variety of other antigen presenting cell types.

Although we uncovered this processing activity using an antigen proteolysis assay, it is possible that it also plays a role in invariant chain processing as well. Splenocytes from cathepsin D gene targeted mice continued to produce invariant chain processing products even when all known cysteine protease activity were also suppressed by leupeptin⁷. Villadangos *et al* suggested that other non-cysteine proteases (besides cathepsin D) must be initiating Ii (invariant chain) cleavage. Cathepsin E is one possible candidate but so too is AEP since, although it is a cysteine protease, it is completely resistant to leupeptin (Fig 1a). Intact p31 Ii is readily cleaved by AEP *in vitro* and we are currently assessing the possibility that AENK also interferes with Ii processing. However, the differential effect of the AENK inhibitor on T cell clones and the fact that pre-digestion of antigen with AEP abolished the inhibitory effect of the AENK inhibitor argues that its primary inhibitory effect in our studies was on TTCF processing.

25

unbroken cells removed by centrifugation at 2,000 g for 10 minutes. A membrane pellet was collected at 40,000 g and solubilised in 50 mM citrate buffer, pH 5.5 containing 0.1% CHAPS (3-[(cholamidopropyl)dimethylammonio]-1-propane-sulphonate). The extract
5 was centrifuged at 2,000 g for 20 minutes and then applied to a Mono-S column (Pharmacia[?]). Fractions were eluted with a gradient of NaCl and monitored for TTCF processing activity.

Proteins and peptides. A histidine tagged derivative of the C terminal
10 domain of tetanus toxin was prepared^{9,10} and purified¹⁰ as described. This protein has residues 872-1315 of the complete toxin (1-1315) preceded by the sequence MGHGHHHHHHHHHHSSGHIEGRHI. Mutagenesis of residues 1184/5 was performed using template EH106 obtained by cloning the His-TTCF (Reference 10) as an XbaI/BamHI fragment into pSL1180
15 (Pharmacia). Site directed mutagenesis of residues 1184/85 was performed according to the method of Mikaelian and Sergent¹¹ using the mutagenic primer CGC TAC ACT CCG AAC GCG GCG ATC GAT TCT TTC GTT and flanking primers M13 rev (AGCGGATAACAATTTCACACAGGA) and M13 seq
20 (GTAAAACGACGGCCAGT). After sequencing to confirm mutagenesis, recloned back into pET16B for expression. Tetrapeptides were synthesised using Fmoc chemistry leaving the C-terminus amidated and the N-terminus retaining the Fmoc group. LHVS was a kind gift from Hidde Ploegh, MIT.

25

Antigen presentation. Peripheral blood mononuclear cells were prepared by Ficoll/Paque centrifugation and used fresh. T cell clones specific for TTCF were established from donor A.K. according to¹². Epitope

References for Example

1. Chen, J.M., *et al* (1997) *J. Biol. Chem.* **272**, 8090-8.
2. Kembhavi, A.A., Buttle, D.J., Knight, C.G. & Barrett, A.J.
5 (1993) *Arch. Biochem. Biophys.* **303**, 208-13.
3. Dalton, J.P., Holo Jamriska, L. & Brindley, P.J. (1995)
Parasitology **111**, 575-80.
4. Riese, R.J., *et al* (1996) *Immunity* **4**, 357-66.
5. Watts, C. (1997) *Annu Rev Immunol* **15**, 821-50.
- 10 6. Fineschi, B. & Miller, J. (1997) *Trends Biochem Sci* **22**, 377-382.
7. Villadangos, J.A., Riese, R.J., Peters, C., Chapman, H.A. &
Ploegh, H.L. (1997) *J. Exp. Med.* **186**, 549-60.
8. Davidson, H.W., West, M.A. & Watts, C. (1990) *J Immunol* **144**,
4101-9.
- 15 9. Makoff, A.J., Ballantine, S.P., Smallwood, A.E. & Fairweather,
N.F. (1989) *Bio/Technology* **7**, 1043-1046.
10. Hewitt, E.W., *et al* (1997) *J. Immunol.* **159**, 4693-9.
11. Mikelain, I. & Sargent, A. (1992) *Nucleic Acids Res.* **20**, 376.
12. Lanzavecchia, A. (1985) *Nature* **314**, 537-539.
- 20 13. Pond, L. & Watts, C. (1997) *J. Immunol.* **159**, 543-53.

CLAIMS

1. A method of modulating the immune response in a patient in need of such modulation, the method comprising administering to the patient an effective amount of an inhibitor of asparaginyl endopeptidase.
2. A method according to Claim 1 wherein the patient has or is at risk of a disease which involves MHC Class II molecules.
3. A method according to Claim 1 or 2 wherein the disease is an autoimmune disease.
4. A method according to Claim 3 wherein the disease is rheumatoid arthritis.
5. A method according to any one of the preceding claims wherein the inhibitor is a competitive inhibitor.
6. A method according to Claim 5 wherein the competitive inhibitor is a peptide comprising is an asparagine-containing peptide.
7. A method according to Claim 6 wherein the peptide is an N and C-terminal blocked peptide Ala-Glu-Asn-Lys-NH (AENK) or Lys-Asn-Asn-Glu-NH (KNNE).
8. A method according to Claim 1 to 4 wherein the inhibitor is a non-competitive or irreversible inhibitor.

14. Use of an inhibitor of asparaginyl endopeptidase in the manufacture of a medicament for modulating the immune response in a patient in need of such modulation.

5

15. Use according to Claim 14 wherein the patient has or is at risk of a disease which involves MHC Class II molecules.

10 16. Use according to Claim 14 or 15 wherein the disease is an autoimmune disease.

17. Use according to Claim 16 wherein the disease is rheumatoid arthritis.

15 18. Use according to any one of Claims 14 to 17 wherein the inhibitor is a competitive inhibitor.

19. Use according to Claim 18 wherein the competitive inhibitor is a peptide comprising is an asparagine-containing peptide.

20

20. Use according to Claim 19 wherein the peptide is an N and C-terminal blocked peptide Ala-Glu-Asn-Lys-NH (AENK) or Lys-Asn-Asn-Glu-NH (KNNE).

25 21. Use according to any one of Claims 14 to 17 wherein the inhibitor is a non-competitive or irreversible inhibitor.

30. A method according to any one of Claims 27 to 29 the method further comprising the step of determining whether the so selected compound is capable of substantially inhibiting the loading and presentation of peptides on an appropriate Class II MHC molecule-containing cell.

31. A method according to Claim 30 wherein it is determined whether the so selected compound is capable of substantially inhibiting T cell activation by an appropriate Class II MHC molecule-containing cell.

32. A non-human transgenic animal wherein a gene encoding asparaginyl endopeptidase has been modified and the animal expresses substantially no asparaginyl endopeptidase from said gene.

33. A non-human transgenic animal according to Claim 32 which is a mouse.

34. A non-human transgenic animal according to Claim 32 or 33 further comprising a genetic background which predisposes to an autoimmune disease either spontaneously or upon administration of protein antigen.

35. A non-human transgenic animal according to Claims 32 or 33 further transgenic for a human Class II MHC molecule and, optionally, further transgenic for human CD4.


26-03-98 15:54 01159 552201
 26/03 '98 THU 16:00 FAX 01159 552201
 22/03 '98 SUN 19:09 FAX 01382 345783

P.39
 ERIC POTTER CLARKSON
 WELLCOME TRUST BLD

R-240 Job-974

039
 01

Fig 1



26-03-98 15:54

01159 552201

P.40

R-240

Job-974

26/03 '98 THU 16:00 FAX 01159 552201

ERIC POTTER CLARKSON
WELLCOME TRUST BLD

040
001

22/03 '98 SUN 19:10 FAX 01382 345783

Fig 1c








Fig 2



26-03-98 15:54 01159 552201
26/03 '98 THU 16:01 FAX 01159 552201
22/03 '98 SUN 19:10 FAX 01382 345783

P.42
ERIC POTTER CLARKSON
WELLCOME TRUST BLD

R-240

Job-974

042
01

Fig 3a





Fig 36







Fig 3c


Figure 4 (page 1 of 6)

Peptide chloromethylketones (ref 5)

(i) Acetyl-tyrosyl-valyl-alanyl-asparaginyl-chloromethylketone
(analogous to ICE protease inhibitor YVAD-cmk)




(ii) Acetyl-alanyl-glutamyl-asparaginyl-chloromethylketone



(iii) Acetyl (or benzyloxycarbonyl)-(X)_n-Asparaginyl-chloromethylketone

Where X = any amino acid



Peptidyl diazomethanes (refs 3,4) (have the general structure: R- $C(=O)CHN_2$)

Cc1ccccc1COCC(=O)N[C@@H](Cc2ccc(C)cc2)C(=O)N[C@@H](Cc3ccc(C)cc3)C(=O)N[C@@H](Cc4ccc(NC(=O)c5ccc(O)cc5)cc4)C(=O)CN
$$\text{C}_6\text{H}_5\text{CH}_2\text{O}-\text{C}(=\text{O})-\text{NH}-\text{CH}(\text{CH}_3)-\text{C}(=\text{O})-\text{NH}-\text{CH}(\text{CH}_2\text{CH}_2\text{COO}^-)-\text{C}(=\text{O})-\text{NH}-\text{CH}(\text{CH}_2\text{CH}_2\text{NH}_2)-\text{C}(=\text{O})-\text{CHN}_2$$
$$\text{BI}-(\text{X})_n-\text{NH}-\text{CH}-\underset{\text{O}}{\overset{\text{CH}_2}{\text{C}}}-\text{CHN}_2$$


818

Figure 4 (page 3 of 6)

Peptide vinyl sulphones (ref 6)

(i) Morpholinurea-leucyl-asparaginyl-vinylsulphone-phenyl


(Acetyl or benzyloxycarbonyl can replace morpholinurea)



MU = morpholinurea

(ii) Morpholinurea-alanyl-glutamyl-asparaginyl-vinylsulphone-phenyl

(Acetyl or benzyloxycarbonyl can replace morpholinurea)



(iii) BI-(X)_n-asparaginyl-vinylsulphone-R

Where BI = N-terminal blocking group (acetyl, morpholinurea or benzyloxycarbonyl, X = any amino acid and R = alkyl or aryl terminating group.






Figure 4 (page 4 of 6)

Peptidyl (acyloxy) methanes (ref 7)



(i) Z-Phenylalanyl-asparaginyl-CH₂OCO-[2,6-(CF₃)₂Phenyl

(ii) Z-Phenylalanyl-asparaginyl-CH₂OCO-[2,4,6-(CH₃) Phenyl



(ii) Z-alanyl-glutamyl-asparaginyl-CH₂OCO-[2,6-(CF₃)₂Phenyl

(iv) Z-alanyl-glutamyl-asparaginyl-CH₂OCO-[2,4,6-(CH₃) Phenyl




(iv) Z-(X)n-asparaginyl- CH₂OCO-R

Where X=any amino acid and R=[2,6-(CF₃)₂Phenyl or [2,4,6-(CH₃) Phenyl
or other acyloxy methane group


Figure 4 (page 5 of 6)

N,O-diacyl hydroxamates (ref 8)

(i) Z-Glycyl-asparaginyl-NHO-benzoyl(4-OCH₃)



(ii) Z-alanyl-glutamyl-asparaginyl-NHO-CO-lysine-NH



(iii) Z-(X)_n-asparaginyl-NHO-CO-R

Where Z= benzyloxycarbonyl or other blocking group, X= any amino acid, and R= any O-acyl group.






Figure 4 (page 6 of 6)

Peptide aldehydes (refs 1 & 2) :

(i) Acetyl-leucyl-leucyl-aspariginal



(ii) Acetyl-alanyl-glutamyl-aspariginal



(iii) Acetyl (or other blocking group)-(X)_n-Aspariginal

—where X denotes any amino acid(s) in peptide linkage.

Elastatinal also blocks AEP. A more specific variant would be:

(iv)





Figure 5 (page 1 of 6)



E-64

Structure: L-trans-epoxysuccinyl-leucylamide-(4-guanido)-butane or
N-[N-(L-trans-carboxyoxiran-2-carbonyl)-L-leucyl]-agmatine



Inhibition spectrum: Irreversible inhibitor of cysteine proteinases. Does not inhibit serine proteinases.

Mechanism of action: Forms a thioether bond with the thiol of the active cysteine (1:1 enzyme/inhibitor molar ratio)

Properties: E-64 is soluble in aqueous solutions (stock solution 1 mM). Stable from pH 2.0 to pH 10.0 but unstable in ammonia or strong acids, which destroy the epoxide ring. Excellent active-site titrant of cysteine proteinases. Originally isolated from the culture medium of a sold mold, *Aspergillus japonicus*.
MW: 357.4

Suggested final concentration: 1-10 μ M



[Back to PROLYSIS home page](#)

~~SECRET~~

13/18

Figure 5 (page 2 of 6)

Leupeptin	
Structure: Acetyl-leucyl-leucyl-arginal	
<p>Chemical structure of Leupeptin (Acetyl-leucyl-leucyl-arginal) is shown. The structure consists of a tripeptide chain with an acetyl group at the N-terminus and an arginal group at the C-terminus. The side chains are two isobutyryl groups (from leucine) and one 3-aminopropyl group (from arginine).</p>	
Inhibition spectrum: inhibits serine (trypsin ($K_i=13\ \mu\text{M}$), plasmin, porcine kallikrein) and cysteine proteinases (papain, cathepsin B). Does not inhibit chymotrypsin and thrombin.	
Mechanism of action: Competitive and reversible inhibitor. Inhibition may be relieved by an excess of substrate.	
Properties: Soluble in water, ethanol, acetic acid and DMF (Stock solution: 10 mM) MW: leupeptin: 426.6; leupeptin hemisulphate monohydrate: 542.7	
Suggested final concentration: 1-10 μM (0.5-1 $\mu\text{g/ml}$)	



[Back to PROLYSIS home page](#)


~~SECRET~~

14/18

Figure 5 (page 3 of 6)

Antipain

Structure: [(S)-1-Carboxy-2-Phenyl]-carbamoyl-Arg-Val-arginal




Inhibition spectrum: Inhibits papain, trypsin and plasmin to a lesser extent. More specific for papain and trypsin than leupeptin. The inhibitory potency of antipain is 100-fold higher than that of elastinal.

Mechanism of action: Formation of a hemiacetal adduct between the aldehyde group of the inhibitor and the active serine of the proteinase.

Properties: Soluble in H₂O, methanol and DMSO (Stock solution: 10 mM). Stable at -20° C.
MW: 604.7 for antipain; 677.6 for antipain dihydrochloride

Figure 5 (page 5 of 6)

TLCK
Structure: Tosyl Lysyl ChloromethylKetone: 1-Chloro-3-tosylamido-7-amino-2-heptanone

Inhibition spectrum: Irreversible inhibitor of trypsin. Also inhibits some serine proteases (kallikrein, thrombin, plasmin) and some cysteine proteases such as papain, bromelain or ficin. Does not inhibit chymotrypsin and zymogens.
Mechanism of action: Requires an active enzyme and forms a covalent bond with His of the active site. Does not react with zymogens so addition of TLCK in a crude extract inactivates only active protease. Does not react with protease-inhibitor complexes.
Properties: TLCK salts are soluble in water up to 20 mg/ml. More stable at pH less or equal to 6.0. Soluble up to 5 mg/ml in methanol or to 1 mg/ml in NaCl 0.15 M. MW: 369.3 (TLCK.HCl)
Suggested final concentration: 50 µg/ml




Back to PROLYSIS home page

Figure 5 (page 6 of 6)

TPCK

Structure: Tosyl Phenylalanyl ChloromethylKetone:
1-Chloro-3-tosylamido-4-phenyl-2-butanone



Inhibition spectrum: Irreversible inhibitor of chymotrypsin. Also inhibits some proteases cleaving substrates with a Phe at position P1 and some cysteine proteases such as papain, bromelain or ficin. Does not inhibit trypsin and zymogens.

Mechanism of action: Requires an active enzyme and forms a covalent bond with His of the active site. Does not react with zymogens so addition of TPCK in a crude extract inactivates only active protease. Does not react with protease-inhibitor complexes.

Properties: TPCK is soluble in ethanol up to 20 mg/ml but poorly in water. It is more stable at slightly acidic or neutral pH. It is destroyed in less than 30 min. at pH 9.0.
MW: 351.9

Suggested final concentration: 100 µg/ml



[Back to PROLYSIS home page](#)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.